Introduction: Influenza is a contagious acute viral disease of the respiratory tract that causes fever, headache, muscle aches and cough. One of the unique features of influenza virus is antigenic variation in viral protein neuraminidase (NA) which causes emergence of new virus variants. NA is responsible for the release and spread of progeny virions. Due to the continuous changes of NA genes, vaccine strains must be re-selected annually. Methods: Complete NA amino acid sequences of 97 strains circulating from 2006 to 2013 in Iran were downloaded from NCBI. The sequences were edited and classified by the year of isolation and their diversity and important changes as well as changes in the predicted ligand binding sites and their resistance to anti-NA drugs, were analyzed. Bioinformatics software such as MEGA6.0, BioEdit, DNAsisMAX and DNAstar were used for the sequence alignments and phylogenetic analyses. Web-based analysis such as SWISS-MODEL, Phyre2 and 3DLigandSite were used for evaluation of the second and third protein structures and prediction of the ligand binding sites. Results: The results showed that 2009 could be considered as an important transition year which caused to classify the isolates into two different distinct groups. This shows the importance of changes made during possible mutations in the genomic structure of the virus which have made it antigenically different from the previous years. Anti-NA drug resistance was observed in 2009. This pandemic strain has become dominant in the following years and is used as a standard vaccine strain from 2010 onwards. Conclusion: The results obtained in this study can aid in better understanding of the antigenic evolution of H1N1 influenza viruses and can potentially accelerate the selection of the vaccine strains.
INTRODUCTION
Influenza is a contagious acute viral disease of the respiratory tract that causes fever, headache, muscle aches, sweating, runny nose, sore throat and cough. It is caused by infection with type A or B influenza virus almost every year [1] . Influenza A viruses are enveloped viruses which belong to the Orthomyxoviridae family with segmented genome made of eight single-stranded negative RNA segments from 890 to 2,341 nucleotides that encode 10 and in some cases, 11 proteins [2] . The classification and nomenclature of influenza A viruses are based on the type of hemagglutinin (HA) and neuraminidase (NA) glycoproteins which are presented on the surface membrane [3] . To date, 16 serologically-distinct HA types and 9 different NA types have been described. Recently, a new HA subtype (H17) has been identified in Bats in South America [4] . NA and HA are two main external transmembrane glycoproteins, extended from the surface of the virus envelope.
These two antigens are the most variable antigens that cause protective immunity. HA is the receptor binding glycoprotein which mediates membrane fusion process [5] . NA is responsible for assisting in the virus entry and the release and spread of the progeny virions [6] [7] [8] . In fact, NA is the component of the virus membrane with enzymatic activity which is involved in the spread of influenza infection from cell to cell [9, 10] . At the late stages of the viral life cycle, NA removes sialic acids from the virus progeny and the infected cells, thus prevents the virus aggregation and promotes its detachment and release [11] . Antigenic variation is a significant feature in influenza [1] . In other words, changes in proteins of virus specially (i.e. HA and NA) would cause variants that are new in the population. Every year or every few years, occurrences of point mutations that are minor antigenic changes leads to the antigenic drift. The antigenic shifts are major antigenic changes, leading to completely new virus variants that might have a pandemic potential. Vaccination and antiviral drugs are main methods for prevention and treatment of influenza disease. Continuous changes of HA and NA genes (antigenic changes) have made vaccine strains selection challenging and they must be selected annually, based on the currently circulating strains. Antiviral drugs, especially NA inhibitors, are the valuable addition to the options used to control the influenza infection [12, 13] . Collecting, reporting and analysis of epidemiologic data obtained from inspection of antigenic changes in each year is an important procedure that global influenza surveillance program has emphasized on it and could be useful in selection of the vaccine strains [14, 15] . The recognition of the importance of anti-NA antibodies in immunity to influenza has led to studies of small molecules that can block the functions of NA, with a view to the antiviral drug development [16] . In the case of NA, the enzyme inhibitors; Zanamivir (GG167; Relenza, GlaxoSmithKline, Research Triangle Park, NC, USA) and Oseltamivir (GS4104; Tamiflu; Genentech, South San Francisco, California and Chugai Pharmaceutical Co., Japan) [17] are already licensed as antiinfluenza drugs and are widely marketed for therapeutic and prophylactic uses [18] [19] [20] [21] . They act specifically against all subtypes of influenza A and influenza B NAs that prevent the virus from being released from the infected cells. Although the emergence of antiviral resistance is generally associated with drug treatments, due to the drug pressure, it may emerge coincidentally during a virus evolution when mutations are either neutral or confer an evolutionary advantage on the (epidemic) virus variant and are maintained in the absence of the drug pressure. The emergence and spread of anti-NA drug resistant viruses that should be monitored, emphasizes the importance of developing other effective agents against different viral targets and application of antiviral combinations to reduce the emergence of the resistance [22] . In this study which was conducted for the first time in Iran, the complete amino acid sequences of NA antigen of type A H1N1 influenza viruses available in NCBI GenBank from 2006 to 2013 in Iran were inspected to define the prevalence library and to study the trend of changes in NA sequences while determining their relation with the changes of the virus using bioinformatics methods. The relations of gene alterations and the tertiary structure (3D model) with the relevant regions in NA were also studied. Furthermore, the emergence of anti-NA drug resistance was inspected in each year. The relationship of changes of each year's isolates to the vaccine strain of that year was also investigated.
MATERIALS and METHODS
Complete amino acid sequences (complete CDS) of NA antigen of human H1N1 influenza virus available in NCBI GenBank (http://www.ncbi.nlm.nih.gov) from 2006 to 2013 in Iran were downloaded and saved in FASTA format for creation of required data bank. All downloaded sequences were edited using DNASIS MAX 3.0 software (Hitachi Pharmacia, Hitachi Software Engineering Company, Yokohama, Japan) to have proper and identical sequences in terms of name and format for comparison and performing of the intended analyses. Totally, 97 sequences from 16 provinces of Iran were downloaded, edited and classified based on the year of isolation. The sequences were aligned based on ClustalW method using BioEdit 7.1 program [23] . The Molecular Evolutionary Genetic Analysis (MEGA 6.0) software (http://www.megasoftware.net) was used to analyze the sequence alignments and the evolutionary distances between the strains were computed with the same software using the maximum composite likelihood method for evaluation and exact comparison of the sequences, determination of conserved and variable regions and similarities and differences [24, 25] . Megaline-Dnastar software (Expert Analysis Software for PC, Inc., USA) was used for construction of phylogenetic trees by UPGMA (unweighted pair group method with arithmetic means) method. Using the percent similarity/divergence matrix created by BioEdit program in each year, the sequences with the highest and lowest similarity with other sequences of that year were selected as distinct sequences for comparison and analysis. Then evaluation of secondary and tertiary protein structure and prediction/determination of the ligand binding sites, type and number of the ligand(s) of distinct sequences of each year were done using following web-based analysis software: SWISS-MODEL (http://swissmodel.expasy.org) [26] 
RESULTS
By investigating the results of sequence alignments and phylogenetic trees and percent similarity/divergence matrices and predicted secondary and tertiary structures (3D structures) of the ligand binding sites of distinct sequences of each year (data not shown), it was found that from 2006 to 2008, the sequences are identical and there is no change in the ligand binding sites, or the type and number of the ligands. In 2009, with respect to the occurrence of 2009 H1N1pandemic, by studying the available similarities and differences in alignments of the sequences ( Fig.1) and by investigating the phylogenetic tree of the 2009 isolates ( Fig. 2) , it was found that influenza isolates of Iran, are located in two entirely distinct and separated branches and form two different groups in terms of amino acid properties. The remarkable point is that, the first group, in terms of amino acid sequences and gene positions, is similar to the sequences of 2006-2008 isolates and in some cases is entirely identical while the second group is similar to the sequences of 2010-2013 isolates and in some cases is entirely identical. This similarity, in terms of alignment analyses of amino acid sequences and the structure of phylogenetic tree between the two different groups in 2009, shows the importance of changes in the genomic structure of the virus in this year which were possibly due to mutations in the genome and the occurrences of frame shift or gene shuffling, causing different sequences and a new group. This new group became dominant in the following years, with significant amino acid changes in NA genome that resulted in isolates with different clinical properties. It was also found that, in 2009, the distinct sequence which had the highest similarity (approximately 99%) with the other sequences of this year (ADJ18168) had also the highest similarity with the sequences of the following years isolates (i.e. 2010-2013) and the distinct sequence which had the lowest similarity (approximately 81%) with the other sequences of 2009 (ACY01439) had the highest similarity with the sequences of the previous year's isolates (i.e. 2006-2008) ( Table 1 ). This can explain the domination of 2009 pandemic strain from 2010 onwards. Residues within the active site are highly conserved among all of the NA subtypes, including 8 charged and polar residues (Arg118, Asp151, Arg152, Arg225, Glu277, Arg293, Arg368 and Tyr402). They interact with the substrate directly at the catalytic site. The structure of catalytic site is stabilized and supported by the conserved framework residues (Glu119, Arg156, Trp179, Ser180, Asp/Asn199, Ile223, Glu228, His275, Glu278, Asn295 and Glu425) [33, 34] . It was found that the catalytic site residues were conserved from 2006 to 2013 and the framework residues were also conserved except for some cases in 2009 that H275Y mutation, which is the most common molecular marker of NA drug resistance, has occurred. Besides monitoring of the naturally occurring changes in NA and its respective genes, monitoring of mutations especially those associated with resistance to the NA inhibitors is necessary. Antigenic changes and mutations in the gene of NA protein often cause resistance to the available anti-influenza drugs in influenza viruses. Zanamivir and Oseltamivir that inhibit the function of NA are used as antiviral drugs for the prevention and treatment of influenza [35] . As mentioned above, H275Y mutation is the most prevalent molecular marker of drug resistance to Oseltamivir that occurs in or near the active site of NA and decrease the sensitivity of NA and virus to this drug [36] . We found that this mutation was occurred in 3 cases in 2009. Other mutations associated with the resistance to anti-NA drugs were also inspected; however none of them was observed (Table 3) . Molecular and phylogenetic analyses were also performed to reveal the relationship of changes of each year's isolates to the vaccine strains (Table 4 ). It was found that all changes and the obtained results of each year were in compliance with and were observed in the standard vaccine strain of that year and the seasonal isolates turned out to be closely related to the corresponding vaccine strains. This means that studying and identifying the antigenic changes of the virus in each year can be used for the prediction of changes in future and designing new vaccines or anti-influenza drugs. Table 3 . Mutations associated with resistance to anti-NA drugs.
Mutations associated with resistance to anti-NA drugs Year E19V R152K D199N I223V/R S247N H275Y R293K N295S 2006 
DISCUSSION
The selection of influenza vaccine strains and the development of new vaccines have been always a demanding task because of the antigenic changes of influenza viruses. Due to continuous and high mutation rate in NA, studying the changes in important sites of NA in the available sequences of different virus strains in a specified time period using conventional bioinformatics methods, can provide useful and important information about the trend of changes for the virologists and the public health authorities. Such insights can help to monitor the emergence of new influenza variants and to detect new antigenic changes occurring in NA protein which are important for updating the vaccine composition. In conclusion, our findings suggest that the 2009 H1N1 pandemic strain might continue to mutate in its NA gene and create new dominant strains with the potential to cause pandemics in the future. Therefore, conduction of this study was important to assess the extent of diversity of the circulating strains and to analyze the amino acid changes and the tertiary structures which can change the function of the virus and its virulence or pathogenicity. This also emphasized the importance of continuous monitoring of influenza A H1N1 virus strains (specially the A (H1N1) pdm09 strain) in different geographical areas in order to get better selection of the vaccine strain for the upcoming seasons. To the best of our knowledge, this study was done for the first time in Iran and the obtained results can be potentially useful for the epidemiological studies, as well as for better understanding of the antigenic evolution of H1N1 influenza viruses and the prediction of changes in the future that together can help to select the proper vaccine strains or to design new effective anti-influenza drugs.
